Charles Morrison, PhD

Senior Epidemiologist

Areas of expertise

  • Contraceptive technologies
  • HIV prevention
  • Sexually transmitted infections
  • Clinical trials design and implementation

Projects & Resources

  • FHI 360 developed and introduced innovative HIV prevention technologies — including microbicides and antiretrovirals — and worked with local partners to address the need for HIV prevention options, particularly for women.

  • FHI 360 has been at the forefront of research to identify an effective microbicide — a substance that could be used in the vagina or rectum to reduce the risk of HIV transmission during sex.

Published Research

  • Serum vitamin D status and bacterial vaginosis prevalence and incidence in Zimbabwean women
    Turner AN, Reese PC, Chen PL, Kwok C, Jackson RD, Klebanoff MA, Fichorova RN, Chipato T, Morrison CS
    Am J Obstet Gynecol 2016 Sep; 215(3): 332.e1-10. [Journal Impact Factor: 4.681]

    Bacterial vaginosis, a highly prevalent vaginal condition, is correlated with many adverse reproductive outcomes. The authors examined the association between vitamin D status and prevalence of bacterial vaginosis, separately for pregnant and nonpregnant women. Among reproductive-age Zimbabwean women, insufficient vitamin D was not associated with increased bacterial vaginosis prevalence or incidence. Identification of factors leading to high bacterial vaginosis prevalence is urgently needed.

  • Biomarkers of cervical inflammation and immunity associated with cervical shedding of HIV-1
    Mauck C, Chen PL, Morrison CS, Fichorova RN, Kwok C, Chipato T, Salata RA, Doncel GF
    AIDS Res Hum Retroviruses 2016 May; 32 (5): 443-51. [Journal Impact Factor: 2.325]

    Cervicovaginal HIV shedding is associated with increased female-to-male and mother-to-child transmission. The authors identified a specific immune mediator profile that is associated with the risk of cervical HIV shedding. This information could be used to develop antimicrobial agents or identify women at high risk of onward HIV transmission.

  • Determining hepatitis C virus incidence in populations: An important tool of epidemic control (editorial)
    Mastro TD, Morrison CS, Hamilton CD
    Journal of Infectious Diseases. 2016; 214 (3): 339-40.

    There are an estimated 130–150 million people living with chronic hepatitis C virus (HCV) infection worldwide. Traditional methods of incidence determination are complex and expensive, involving long-term, prospective follow-up of cohorts of HCV-negative persons. This editorial reviews the data of a multiassay algorithm for estimating the incidence of HCV infection; modeled after algorithms to determine HIV infection incidence from cross-sectional surveys. The authors present evidence that reinforces the need for improved HCV infection incidence estimates to assess progress made as increased investments are made in treatment and prevention programs.

Explore More Related to Charles Morrison, PhD